Form 4: Mirum Pharmaceuticals CEO Trades Shares

Mirum Pharmaceuticals CEO Christopher Peetz reported transactions involving company stock, including the acquisition of shares and the sale of a significant number of shares under a Rule 10b5-1 trading plan.

Summary

• Christopher Peetz, CEO of Mirum Pharmaceuticals, Inc., engaged in several stock transactions on July 6, 2026.
• He acquired 20,000 shares of common stock at a price of $2.936 per share.
• Concurrently, he sold a total of 27,999 shares of common stock through multiple transactions at weighted average prices ranging from $121.65 to $124.79.
• These sales were executed under a Rule 10b5-1 trading plan adopted on March 2, 2026.
• Following these transactions, Peetz beneficially owns 202,175 shares directly and 187,500 shares indirectly through The Peetz Family Trust.
• A vested employee stock option for 20,000 shares, with an exercise price of $2.936 and an expiration date of March 11, 2029, is also held by Peetz.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While there is an acquisition of shares, the significant volume of sales under a pre-arranged plan balances out any strongly positive or negative sentiment.

Positives

• Acquisition of 20,000 shares at a lower price point ($2.936) suggests potential confidence in future value or a strategic purchase.
• The CEO continues to hold a substantial number of shares (202,175 directly, 187,500 indirectly), indicating continued significant beneficial ownership.

Negatives

• Sale of 27,999 shares, even under a pre-arranged plan, represents a reduction in the CEO's direct holdings.
• The sale prices were significantly higher than the acquisition price, indicating a realization of gains, but also a reduction in potential upside participation for the CEO.

Risks

• The Rule 10b5-1 plan indicates a pre-determined strategy for selling shares, which could be interpreted as a signal of potential future price moderation or a need for liquidity by the reporting person.
• While not explicitly stated as a risk in the filing, significant insider selling can sometimes be perceived negatively by the market, potentially impacting investor sentiment.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the acquisition of shares at a lower price point and the sale of shares under a Rule 10b5-1 plan are actions taken by management that may reflect their view on the company's future prospects.

Management Comments

• The stock option is fully vested.
• Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026.
• Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the Issuer, or any security holder of the Issuer for specific sale transactions.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common in the biopharmaceutical sector as executives manage personal portfolios while adhering to regulatory requirements. The significant difference between the acquisition price and sale prices for Mr. Peetz's shares could reflect the company's performance or market conditions impacting its valuation.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO, even under a 10b5-1 plan, might be scrutinized by investors. However, the continued substantial ownership and the acquisition of shares could be viewed positively.
• Employees: The CEO's stock option is vested, which is a standard component of executive compensation.
• Management: The transactions reflect the execution of a pre-planned strategy for managing personal equity holdings.

Next Steps

• The Rule 10b5-1 plan may continue to execute further sales as per its terms.
• The company may provide full information regarding the specific prices of shares sold upon request.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Transaction, Mirum Pharmaceuticals, Christopher Peetz, CEO, Rule 10b5-1, Common Stock, Stock Option